Prospective AI Versioning Standard Needed: Post
A Clinical Trial Vanguard online post explains the need for a prospective artificial intelligence (AI) versioning standard for investigational use. “Every model update deployed to a trial system should require a version identifier logged in the trial master file,” the post says, “a documented assessment of whether the update constitutes a significant change under FDA’s investigational device change guidance, and a statistical impact analysis confirming that pre-specified endpoints remain interpretable under the updated model. That is not bureaucratic excess. It is the minimum evidentiary hygiene required to defend a primary endpoint in front of an FDA advisory committee.”
The post describes FDA’s 4/2026 real-time clinical trial initiative as “genuinely ambitious. The agency is signaling that it wants AI and data science integrated into trial infrastructure at the safety monitoring level, not just as an analysis tool, but as a live operational component. That posture is understandable given the evidence that traditional safety monitoring misses early signals that real-time AI surveillance could catch. But ambition and infrastructure are different things.”
The International Council on Harmonization M15 framework on model-informed drug development and FDA’s existing adaptive design guidance together provide the conceptual scaffolding for the needed guidance, the post says. What is missing, it adds is a sponsor-facing operational standard that specifies how to document AI model provenance within an eClinical system, how to trigger institutional review board notification when a model update affects patient-facing decision support, and how to handle retrospective sensitivity analyses when undisclosed updates are discovered during audit.
“FDA’s real-time clinical trial announcement of 4/28 is the starting gun, not the finish line,” the post concludes. “Sponsors who treat it as a permission slip to embed continuously updating AI into confirmatory trials without versioning controls will discover, at the worst possible moment — the complete response letter stage — that the trial they ran is not the trial the agency can evaluate. The algorithm kept learning. The protocol did not.”